“Same Molecule” Is Not the Same Product: Compounded GLP-1 Impurities

“It is the same molecule” is the most common reassurance in the compounded GLP-1 market, and as far as it goes it is true. What it leaves out is that a medicine is a formulation, not just an active ingredient — and the parts it omits are exactly the parts that have been studied. A 2026 analysis looked directly at impurities and potential immunogenicity associated with follow-on and compounded GLP-1 receptor agonists^[1], treating the question as separate from whether the active molecule is correct. That is the right framing, and it is the one this article follows.

Why a peptide has more ways to go wrong

Small-molecule drugs are relatively robust: a tablet of a simple molecule is either the right compound or it is not. Peptides are larger, more fragile, and capable of failing in ways that still leave the right molecule nominally present. They can degrade chemically, they can aggregate, and they can carry related substances left over from synthesis. Work on semaglutide degradation in solution shows how much the surrounding formulation matters — pH, buffer identity, buffer molarity and temperature each influence the degradation observed^[2], which means two preparations of the same peptide need not behave the same way.

Temperature adds a second axis. Thermal stress studies on semaglutide track not only how much intact peptide remains but changes in secondary structure and phase behavior as temperature rises^[3]. Structure matters here in a way it does not for a small molecule: a peptide that has partially unfolded or aggregated is a different object to the immune system even when the chemical inventory looks similar.

The immunogenicity question, stated carefully

Immunogenicity means the potential for a product to provoke an immune response — most commonly anti-drug antibodies. It is a routine part of evaluating any peptide or protein therapeutic, and it is influenced by aggregates and impurities as well as by the molecule itself. That is precisely why the recent analysis paired the two words: impurities and potential immunogenicity are studied together, because the former is one of the drivers of the latter^[1].

The honest reading is conditional rather than alarming. Documenting that a preparation carries impurities capable of contributing to immunogenicity is not the same as demonstrating harm in patients, and this article does not claim otherwise. What it establishes is that the question is real, that it is specific to preparations rather than to molecules, and that it cannot be answered by pointing at the brand product's safety record.

Where the differences come from

What is reasonable to ask

• Which facility prepared it, and under what registration? Sterile compounding operates under defined standards for environment, personnel and process^[4]; knowing who made your vial is the entry point to every other question.
• Is there a certificate of analysis for this batch? A document covering identity, potency and purity for the batch you received is a different thing from a general assurance about the pharmacy.
• What was tested — and was sterility among it? Potency testing and sterility testing are separate. A result for one says nothing about the other.
• What are the assigned storage conditions and beyond-use date? These are the practical expression of the stability work behind your preparation.
• Is the salt form the same? Regulators have previously raised concerns about salt forms of semaglutide appearing in compounded products, which is a question about the active ingredient itself rather than about handling.

A pharmacy that prepared your medicine can answer all of these. Difficulty getting answers is itself informative — not proof of a problem, but a reason to weigh the choice differently.